公开(公告)号：US20250059224A1

公开(公告)日：2025-02-20

申请号：US18760898

申请日：2024-07-01

Applicant: Wake Forest University

Inventor： Ulrich Bierbach ,  Shenjie Zhang ,  Xiyuan Yao ,  Noah H. Watkins

IPC: C07F15/00 ,  A61K31/555 ,  A61K47/54 ,  A61K47/60 ,  A61P35/00

Abstract: Platinum-acridines and analogs thereof as cytotoxic agents for cancer treatment. Also provided methods of using hMATE1 (SLC47A1) as a biomarker to identify tumors that are likely to respond to the agents, and epigenetically sensitizing tumor tissue to anticancer drugs targeting this membrane transporter.

公开(公告)号：US12214012B2

公开(公告)日：2025-02-04

申请号：US16918527

申请日：2020-07-01

Applicant: IMMUTEP S.A.S.

Inventor： Frederic Triebel

IPC: A61K38/17 ,  A61K31/282 ,  A61K31/4745 ,  A61K31/555 ,  A61K45/06 ,  C07K14/705

Abstract: Combined preparations for the treatment of cancer are described. The combined preparations comprise: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor. Methods for the treatment of cancer using the combined preparations are also described.

公开(公告)号：US20250034158A1

公开(公告)日：2025-01-30

申请号：US18041470

申请日：2021-08-14

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Jonathan L. SESSLER ,  Adam C. SEDGWICK ,  Gregory THIABAUD ,  Jonathan ARAMBULA

IPC: C07D487/22 ,  A61K31/555 ,  A61K41/00 ,  A61K49/22

Abstract: The present disclosure relates to manganese containing texaphyrin compounds of the formula (I). Wherein the variables are as described herein. The present disclosure also provides pharmaceutical compositions of the compounds. Also, provided herein are methods of using the compounds in the treatment of cancer including platinum resistant cancer.

公开(公告)号：US20250018060A1

公开(公告)日：2025-01-16

申请号：US18711355

申请日：2022-11-18

Applicant: Christiana Care Gene Editing Institute, Inc.

Inventor： Eric B. Kmiec ,  Byung-chun Yoo ,  Steven Yang ,  Kelly H. Banas

IPC: A61K48/00 ,  A61K31/337 ,  A61K31/475 ,  A61K31/555 ,  A61K33/243 ,  A61P35/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86

Abstract: The disclosure provides recombinant adenoviruses comprising a polynucleotide comprising: a first DNA sequence encoding a guide RNA (gRNA), wherein the gRNA comprises a DNA-binding domain and a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease protein-binding domain, and the DNA-binding domain is complementary to a target sequence in a gene; and a first promoter that is operably linked to the DNA sequence. The disclosure also provides pharmaceutical compositions comprising the adenoviruses described herein. The disclosure further provides a method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical compositions as described herein to the subject.

公开(公告)号：US20250017944A1

公开(公告)日：2025-01-16

申请号：US18381524

申请日：2023-10-18

Applicant: Galera Labs, LLC

Inventor： Jeffery L. KEENE ,  Dennis P. RILEY ,  Robert A. BEARDSLEY

IPC: A61K31/555 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19

Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.

公开(公告)号：US20250009755A1

公开(公告)日：2025-01-09

申请号：US18710916

申请日：2022-11-16

Applicant: Ohio State Innovation Foundation

Inventor： Andre PALMER ,  Katelyn Elizabeth REILLY ,  Megan ALLYN

IPC: A61K31/555 ,  A61K9/00 ,  A61K45/06 ,  A61K47/64 ,  A61P27/02

Abstract: Disclosed are ocular therapeutic compositions as well as methods for treating ocular diseases and injuries using these compositions.

公开(公告)号：US12171769B2

公开(公告)日：2024-12-24

申请号：US17691764

申请日：2022-03-10

Applicant: BioMimetix JV, LLC ,  Duke University

Inventor： Kathleen Ashcraft ,  Mark Dewhirst ,  Ines Batinic-Haberle ,  James D. Crapo

IPC: A61K31/495 ,  A61K31/555 ,  A61K33/243 ,  A61K45/06 ,  A61P17/00 ,  A61P35/00 ,  A61P43/00

Abstract: Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose.

公开(公告)号：US20240408071A1

公开(公告)日：2024-12-12

申请号：US18696916

申请日：2022-09-30

Applicant: NATIONAL CENTRE FOR CELL SCIENCE

Inventor： Girdhari LAL ,  Surojit KARMAKAR

IPC: A61K31/4439 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/555 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

Abstract: The present invention discloses the use of the novel combination comprising HTR2B antagonist and check-point inhibitors/blockers or various classes of chemotherapeutic agents. The present invention also discloses a composition comprising the combination of the present invention. The present combination and composition are found to possess enhanced activity against various cancer, especially tumors, preferably tumors of epithelial origin, selected from the group comprising colon cancer, breast cancer, and melanoma.

公开(公告)号：US12150944B2

公开(公告)日：2024-11-26

申请号：US16979251

申请日：2019-04-30

Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

Inventor： Hongmei Song ,  Xiaoxi Yuan ,  Jing Wang ,  Liang Xiao ,  Tongtong Xue ,  Ping Liu ,  Lichun Wang ,  Jingyi Wang

IPC: A61K47/68 ,  A61K9/00 ,  A61K31/337 ,  A61K31/555 ,  A61P35/00 ,  C07K16/32

Abstract: Disclosed in the present invention is the use of an anti-HER2 antibody-drug conjugate in cancer treatment. Further provided in the present invention is the use of a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of each of the foregoing in the manufacture of a medicament for the prophylaxis and/or treatment of a cancer insensitive or irresponsive to a treatment with a HER2-targeting agent.

公开(公告)号：US12090179B2

公开(公告)日：2024-09-17

申请号：US18159934

申请日：2023-01-26

Applicant: Salspera, LLC

Inventor： Daniel A. Saltzman

IPC: A61K35/74 ,  A61K31/513 ,  A61K31/555 ,  A61K31/675 ,  A61K31/7068 ,  A61K33/243

CPC classification number: A61K35/74 ,  A61K31/513 ,  A61K31/555 ,  A61K31/675 ,  A61K31/7068 ,  A61K33/243

Abstract: A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.